Centre Hospitalier Lyon Sud

The medical center is at the forefront of research in Cystic Fibrosis, focusing on the long-term safety and tolerability of innovative therapies. The center's work in this area aims to enhance the quality of life for patients by exploring new treatment combinations.

• Long-term safety of elexacaftor/tezacaftor/ivacaftor
• Improving patient outcomes

Through its research, the center contributes significantly to the understanding and management of Cystic Fibrosis, offering hope for improved therapeutic strategies.

Specializing in Polycythaemia Vera, the center conducts pivotal trials comparing the efficacy of ruxolitinib with other therapies. This research is crucial in preventing severe complications and improving survival rates in high-risk patients.

• Comparative efficacy of ruxolitinib
• Prevention of major complications

The center's efforts in this field are instrumental in refining treatment protocols and enhancing patient care for those with Polycythaemia Vera.

In the realm of Non-Small Cell Lung Cancer (NSCLC), the center is pioneering studies on the efficacy of combination therapies for advanced stages. This research is vital for patients with specific genetic mutations who have progressed after targeted therapies.

• Combination therapy efficacy
• Targeted therapy progression

The center's work is pivotal in advancing treatment options and improving outcomes for patients with advanced NSCLC.

The center is a leader in exploring Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for ovarian cancer relapse. This innovative approach aims to improve survival rates and offers a promising option for patients with resectable relapses.

• HIPEC efficacy in ovarian cancer
• Survival rate improvement

Through its research, the center is advancing the treatment landscape for ovarian cancer, providing new hope for patients facing relapse.

Focusing on Multiple Myeloma, the center is evaluating the efficacy of elranatamab monotherapy in patients resistant to multiple treatment lines. This research is crucial for developing new therapeutic strategies for refractory cases.

• Elranatamab monotherapy efficacy
• Refractory multiple myeloma

The center's contributions are vital in expanding treatment options and improving outcomes for patients with Multiple Myeloma.

The center is advancing research in the treatment of sinuses and salivary gland tumors, comparing radiotherapy with chemoradiotherapy. This study aims to optimize treatment regimens and improve progression-free survival for patients.

• Radiotherapy vs. chemoradiotherapy
• Progression-free survival

Through its research, the center is enhancing therapeutic approaches and patient outcomes in the treatment of these complex tumors.

In the field of Myelofibrosis, the center is evaluating the combination of pelabresib and ruxolitinib. This research is essential for improving treatment efficacy and offering new hope for patients with this challenging condition.

• Pelabresib and ruxolitinib combination
• Improving treatment efficacy

The center's work is crucial in advancing therapeutic options and enhancing the quality of life for patients with Myelofibrosis.